Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Pulse Biosciences ( (PLSE) ).
On February 27, 2026, Pulse Biosciences, Inc. announced that Chief Commercial Officer Kevin P. Danahy resigned from the company, effective immediately, with the board noting his departure was not due to any disagreement over operations, policies, or accounting practices. The company highlighted Danahy’s role as a key member of senior management and its early commercialization efforts, signaling a notable change in its commercial leadership but no underlying dispute or governance concern tied to his exit.
The most recent analyst rating on (PLSE) stock is a Hold with a $19.50 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held back primarily by weak financial performance (minimal revenue, large losses, and accelerating cash burn), partially offset by strong technical uptrend signals and constructive clinical/regulatory progress discussed on the earnings call. Valuation is also a headwind given negative earnings and no dividend support.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. operates in the medical technology sector, where it is focused on developing and commercializing health-related technologies and products. The company has been advancing early commercialization efforts in its niche, supported by a senior management team that includes roles dedicated to driving market adoption and revenue growth.
Average Trading Volume: 310,014
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.29B
For detailed information about PLSE stock, go to TipRanks’ Stock Analysis page.